Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Trial ID or NCT#

NCT02546102

Status

not recruiting iconNOT RECRUITING

Purpose

ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to evaluate ICT-107 in patients with newly diagnosed glioblastoma. Subjects will be randomized to receive standard of care chemoradiation (temozolomide (TMZ) with either ICT-107 or a blinded control. Reinfusion with the pulsed dendritic cells should stimulate cytotoxic T cells to specifically target glioblastoma tumour cells.

Official Title

A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Reena Thomas
Reena Thomas
Neuro-oncologist
Clinical Professor, Adult Neurology Clinical Professor (By courtesy), Neurosurgery

Contact us to find out if this trial is right for you.

Contact

Sophie Bertrand
Bertrand

View on ClinicalTrials.gov